Perioperative cardiac complications
===================================

Cardiac complications are a major cause of perioperative and late morbidity and mortality, especially in patients undergoing vascular surgery ([@b60]). This is particularly related to underlying ischemic heart disease, which is frequently asymptomatic and the prevalence of which is increasing in many countries. Since the risk factors for coronary artery disease and peripheral vascular disease are the same, patients undergoing vascular surgical procedures are at particularly high risk in developing perioperative cardiac complications ([@b7]; [@b36]). A recent *Vascular Anaesthesia Society* audit identified a perioperative mortality rate of 7.3% in patients undergoing infrarenal aortic surgery with most of these deaths attributable to cardiac events ([@b9]). Unfortunately despite an improvement in the safety of modern anesthesia, better drugs and advances in perioperative patient monitoring, the mortality from myocardial infarction after noncardiac surgery is still high, and is believed to be 10% to 15% ([@b3]). In a cohort of 323 patients with a cardiac history who underwent noncardiac surgery, [@b8] showed that 18 (5.6%) patients developed postoperative myocardial infarction with electrocardiogram and enzyme (creatinine kinase and troponin-T) changes, but only 3 of these were clinically apparent with central chest pain. In this cohort of patients, the great majority of myocardial infarctions occurred within the first 3 days postoperatively ([@b8]). It may be difficult to assess the true incidence of postoperative myocardial infarction, as it is dependent on the specificity and sensitivity of the method of diagnosis ([@b26]), and the fact that some are silent clinically ([@b55]). In a prospective study involving 444 patients with or at high risk for coronary artery disease who underwent elective noncardiac surgery, [@b46] found that postoperative myocardial ischemia increased the odds for long-term (30 days to 2 years after surgery) cardiac events (unstable angina, nonfatal myocardial infarction, cardiac death, surgical coronary revascularization) by 2.2-fold. Timing of surgery following myocardial infarction has some importance, although risk is related more to the functional status of the ventricles than time period since the myocardial infarction. At less than 6 weeks the risk is relatively high as the damaged myocardium is still healing. There appears then to be an intermediate risk period up to 3 months but, in uncomplicated cases, no benefit in delaying surgery beyond this ([@b21]).

The pathophysiology of reversible myocardial ischemia or perioperative myocardial infarction is not entirely clear, and is likely to be multifactorial. The main cause is due to rupturing of the unstable coronary atherosclerotic plaque, leading to thrombus formation, arterial stenosis and occlusion, ischemia of the cardiac muscle which may subsequently lead to myocardial infarction if this is prolonged ([@b60]; [@b15]; [@b75]; [@b63]). Surgical stress imposes extra myocardial workload due to local and systemic effects, such as perioperative blood loss, tachycardia, induction of catecholamines and glucocorticoids, tachycardia, blood pressure lability and pain. Patients with cardiac disease are particularly susceptible and since many of these patients are not symptomatic, it is important to try to identify those at risk and institute risk reduction strategies.

Careful preoperative evaluation can help to determine patients at particular risk, although many costly, potentially hazardous cardiac investigations are probably unnecessary and have poor predictive value. In a study of 32 patients who died within 30 days of vascular surgery, only half had evidence of ischemia on dobutamine stress echocardiography; and in 36% of the patients dobutamine stress echocardiogram did not predict the location of the infarct ([@b58]). Many of the proposed surgeries are urgent and it may not be appropriate to undertake coronary revascularization. Furthermore there is increasing evidence that percutaneous coronary angioplasty and stenting may not be helpful in many patients ([@b11]) and even place some at higher risk. This is probably because risk of myocardial infarction is related more to atheromatous plaque stability than degree of stenosis ([@b2]). Consequently we should probably be less stringent in our criteria for identifying high risk patients and improvement of outcome is most likely using medical therapy to control heart rate and blood pressure, reduce infiammation, and stabilize coronary atheromatous plaques.

Beta blockers induce a shift from free fatty acids toward glucose as the main cardiac energy substrate, thus resulting in an improved energy efficiency and outcome; possess an antiarrhythmic effect and antirenin/angiotensin properties; and have antiinfiammatory qualities. In addition, beta-blockade might blunt the adrenergic surge and reduce the adverse outcomes during surgery. A combination of beta blockers, low dose aspirin and statins is currently most promising and a number of large clinical trials have been looking at these treatments ([@b17]). Statins may also reduce the incidence of stroke after carotid endarterectomy, contrast-induced nephropathy, improve graft survival, and appear to have a good safety profile. Currently statins are probably the most promising group of drugs in this perioperative setting ([@b10]).

The cardiovascular protective properties of statins
===================================================

Atherosclerosis is a multi-factorial systemic disease, with hyperlipidemia as an important risk factor. For more than a decade, statins have been used clinically in lowering elevated levels of cholesterol and thus decreasing the risk for atherosclerosis ([@b27]; [@b22]; [@b6]). Not only are statins highly effective in reducing low-density lipoproteins and cholesterol, they also increase high-density lipoproteins and have additional beneficial effects on systemic atherosclerosis. Statins have pleiotropic effects which improve or restore endothelial function, and can stabilize the atherosclerotic plaques by decreasing oxidative stress and vascular infiammation ([@b69]; [@b43]; [@b42]) ([Table 1](#tbl1){ref-type="table"}).

###### 

Effects of statins

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Lipid lowering effects**decrease cholesterolincrease HDL**Pleiotropic effects**increase endothelial NO synthetasegeneration of ROSdecrease endothelin-1 productionimprove thrombogenic profiledecrease Inflammation (decrease isoprenoid production)decrease CRP levelsinhibition of atherosclerosis
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CRP, C-reactive protein; HDL, high-density lipoprotein; NO, nitric oxide; ROS, reactive oxygen species.

Large multi-centre randomized controlled trials have consistently shown that statins are safe and effective in reducing low-density lipoprotein cholesterol and beneficial in the primary and secondary prevention of coronary heart disease. Between 1994 and 1997, three major trials - the Scandinavian Simvastatin Survival Study (4S 1994), the CARE (Cholesterol and Recurrent Events) Trial ([@b62]) and the LIPID [@b45] have all showed that simvastatin and pravastatin reduced the risk of a recurrent coronary event in patients with established coronary heart disease. The results of CARE and LIPID, with pravastatin, also showed that the benefits of improved survival extended to the majority of patients with coronary heart disease irrespective of their serum cholesterol levels. Since then, further studies including the MRC/BHF Heart Protection Study ([@b28]), the [@b4], and the PROSPER Trials ([@b67]) have also reiterated the same conclusion that statins are beneficial to patients with coronary atherosclerosis, irrespective of their cholesterol levels.

Perioperative use of statins
============================

There are many studies involving a large number of patients to show that perioperative statin use is beneficial. Perioperative statin therapy has been shown to improve short and long-term patient outcome following cardiac and noncardiac surgery ([@b32]). With no clinical studies reporting an increased incidence of adverse effects of perioperative statin use, it appears to be a safe and efficacious therapeutic option ([@b19]).

In a randomized, double-blind, placebo-controlled trial involving 6605 patients receiving a low-saturated fat, low-cholesterol diet, [@b18] showed that lovastatin (20--40 mg daily) reduced the risk for the fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death. In prospectively collected data from 1993 to 1999 involving 5052 patients undergoing percutaneous coronary angioplasty or stenting, [@b14] showed that only 26.5% of the patients were treated with statins, and statin therapy was associated with a statistically significant mortality reduction at 30 days and 6 months after coronary intervention. This study was conducted in the 1990s, and it is likely that the number of patients receiving statin therapy is much higher nowadays. Long-term statin administration was associated with a reduced incidence of adverse cardiovascular outcomes and a decreased need for coronary artery bypass graft ([@b14]).

[@b44] performed a retrospective cohort study for a 2 year period from 2000 using data from 329 hospitals throughout the United States involving 780,591 patients who underwent major noncardiac surgery. In this study, the overall perioperative mortality rate was 2.96%, and, despite the fact that the patients on statin therapy were older, had a higher number of comorbidities, and a higher revised cardiac risk index score than those patients who were not treated, the use of statins during the early perioperative period was associated with a 1% absolute reduction of hospital mortality and a 38% reduction in the odds of inhospital mortality among patients undergoing major noncardiac surgery ([@b44]). Similarly, in a 10 year retrospective case-controlled study involving 2816 patients who underwent major vascular surgery between 1991 and 2000, Poldermans et al found that the risk of perioperative mortality among statin users was reduced 4.5 times compared with nonusers. This reduction in mortality was consistent in subgroup analysis independent of the type of surgery, cardiac risk factors, and cardiovascular therapy, including aspirin and β-blockers ([@b57]). Similar conclusions were reached by [@b52] in a case-controlled study in 75,581 patients who underwent 108,593 noncardiac, nonvascular surgical procedures over a 10 year period between 1991 and 2001, statins were associated with a 60% mortality reduction.

In a prospective, randomized, placebo-controlled, double-blind clinical trial involving 100 eligible consecutive patients scheduled for elective noncardiac vascular surgery in Brazil, [@b20] found that patients taking atorvastatin had a statistically significant reduced rate of cardiac events within 6 months after surgery. In another study examining the effects of different types of statins (simvastatin, fiuvastatin, pravastatin, and atorvastatin) in 211 consecutive patients who underwent major elective vascular surgery between 1998 and 2004, [@b64] found that statins were well tolerated and patients on statins had a more favorable perioperative cardiac outcome. In a 14-year period study involving 511 patients with left ventricular dysfunction undergoing noncardiac vascular surgery, [@b25] found that statins were significantly and independently associated with a reduced incidence of in-hospital cardiac related mortality. The same authors found in a cohort of 1374 patients with peripheral arterial disease that long term high dose statin therapy was associated with an improved outcome both in mortality and cardiac morbidity, irrespective of whether the patients had surgery or not ([@b25]).

Perioperative statin therapy is also associated with favorable perioperative outcomes unique to vascular surgery. [@b66] showed that statin use can reduce the rate of growth of infrarenal aortic aneurysm, although better blood pressure control in statin users in this study could have been a contributing factor as significantly more statin users were on angiotensin-II-antagonist therapy. In a retrospective study involving 510 patients with a median follow-up period of 4.7 years, [@b35] showed that patients receiving both statins and beta-blockers had a four fold reduction in perioperative mortality and nonfatal myocardial infarction after abdominal aortic aneurysm surgery, compared with patients receiving statins alone. In a retrospective review of 446 patients who underwent infrainguinal vascular bypass with a mean follow-up period of 5.5 years, [@b71] found that preoperative statin therapy was associated with less perioperative cardiac and major vascular complications, a shorter length of stay, and improved long-term survival. The findings of these studies are similar to the conclusion from the Statins for Risk Reduction in Surgery (StaRRS) study, a retrospective study with 1163 patients in which perioperative statin therapy was shown to have a highly significant myocardial protective effect in vascular patients, irrespective of their cholesterol levels ([@b53]). In addition, perioperative statin therapy appeared to have a renal protective effect in patients undergoing complex aortic surgery. In 77 patients with normal preoperative renal function requiring suprarenal aortic cross clamping-declamping during vascular surgery, [@b65] showed that postoperative creatinine levels during the 30 days after surgery were significantly lower in statin users than in nonusers, and temporary postoperative hemodialysis was required in 7 patients, all of whom were not on perioperative statin therapy. There is an increasing trend towards endovascular surgery and this may involve the use of large amounts of contrast media with implications for renal function. A study of patients undergoing percutaneous coronary interventions found that pre-procedure statin use was associated with significant reduction in contrast induced nephropathy ([@b37]), although this effect is more controversial ([@b73]). In two recent review articles, the authors concluded that perioperative statin use in high-risk patients undergoing major elective vascular surgery is beneficial and safe, although the dosage and duration of treatment remained undefined ([@b13]; [@b54]).

In a study involving 98 patients who underwent carotid endarterectomy, of whom 43 (44%) were on statin treatment at least 3 months before endarterectomy and 55 (56%) had never received statin treatment, [@b38] showed that perioperative statin therapy was beneficial in that it was associated with reduced intraplaque angiogenesis in the carotid arteries. Intraplaque angiogenesis can cause progression of atherosclerotic plaque and also lead to plaque instability and rupture ([@b33]). The pathophysiology can be applied clinically as intraplaque angiogenesis and vascularization of the carotid plaque can cause ipsilateral neurological symptoms within one month of the surgical procedure and with perioperative and intraoperative evidence of distal embolization ([@b48]). [@b57] showed that statin use reduces perioperative cardiac and cerebrovascular mortality in patients undergoing major vascular surgery. Long term post-operative statin therapy is also beneficial as statins can enhance the rate of apoptosis in neointimal smooth muscle cells and reduce,the rate of myointimal hyperplasia and restenosis ([@b23]). In a single centre study of 2127 primary carotid endarterectomy in 1853 patients between 1989 and 1999, LaMuraglia and colleagues (1995) have shown that lipid-lowering therapy is protective against carotid re-stenosis, and had favorable effects on patient survival.

In a retrospective analysis of 172 consecutive patients who underwent primary autogenous infrainguinal reconstructions with long saphenous vein, [@b1] showed that statin therapy had a beneficial effect on graft patency in a follow-up period of two years. The patients on perioperative statin therapy had a much lower incidence of graft occlusions ([@b1]). In 293 patients who had infrainguinal bypass grafts with either autologous vein or prosthetic conduits, [@b30] showed that patients on statins have an improved graft patency rate, a decreased amputation rate and shorter in-hospital length of stay ([@b71]). Higher doses of statins have additional advantage in patients with peripheral arterial disease ([@b25]).

Contrary to the peri-operative use of statins, Podermans and colleagues (2007) showed in a randomized trial that preoperative coronary revascularization in high-risk patients was not associated with an improved outcome. In order to determine the effect of statin therapy in perioperative cardiac complications and mortality in patients undergoing coronary artery bypass grafts, [@b16] showed in 2666 randomized patients that preoperative statin therapy was associated with a statistically significant reduction in the risk of early cardiac related mortality. Statins did not reduce the risk of early postoperative nonfatal early cardiac complications, but early postoperative statin discontinuation was associated with increased in-hospital mortality ([@b16]).

A recent meta-analysis of 12 retrospective and 3 prospective trials with a total of 223,010 patients and showed that preoperative statin therapy was associated with 38% and 59% reduction in overall mortality after cardiac and vascular surgery ([@b31]). In another meta-analysis of thirty-one randomized studies that compared a statin with placebo or with another statin, statin therapy was associated with a reduced relative risk of all cause mortality, cardiovascular mortality, and fatal myocardial infarction, in patients with cardiovascular disease ([@b72]). However, the potential benefit of statins for low-risk populations is less clear, especially as there may be poor long-term compliance in asymptomatic younger patients.

Statins may also be an effective treatment for sepsis as a result of increased expression of endothelial nitric oxide synthase, in conjunction with down-regulation of inducible nitric oxide synthase ([@b49]). Combined, this results in an increase in physiological concentrations of nitric oxide, thus restoring endothelial function ([@b47]; [@b70]). Laboratory studies have suggested that enhancement of endothelial nitric oxide synthase activity during sepsis may lead to restoration of microvascular tone, maintenance of microvascular integrity, and inhibition of cell adhesion molecules ([@b50]; [@b74]). Other pleiotropic effects, including antioxidant activity and alterations in the development of vascular atherosclerosis, may also contribute to the beneficial effects of statins in this setting.

Timing
======

It is likely that many, if not all, patients undergoing vascular surgery could benefit from statin therapy and surgeons and anesthetists should be alerted to the importance of early identification of patients and initiation of statins, as the run-in time may affect perioperative cardiovascular outcome ([@b57]; [@b20]). The timing of initiation of statin therapy with respect to noncardiac surgery is yet to be defined, as there is no clear guideline on when the drugs should be started. Four weeks should allow time for a maximal clinical effect and identification of efficacy (lipid lowering) or side effects (rhabdomyolysis or raised liver enzymes) ([@b57]). Interestingly no increased incidence of adverse effects has been reported in these trials of patients receiving perioperative statins ([@b40]; [@b57]). There was no statistical difference between postoperative creatine kinase levels between statin users and nonusers ([@b64]).

Postoperatively, all patients in whom long-term statin therapy is indicated should continue their therapy and any patient who has an acute coronary event postoperatively and is not on statin therapy should be considered for treatment initiation as soon as possible ([@b68]). Discontinuation of statin therapy after major vascular surgery is associated with an increased postoperative cardiac risk, suggesting that statin therapy should be continued or resumed early postoperatively ([@b41]). It would be reasonable to continue statins for at least 72 hours postoperatively as this is the time period most likely to be associated with an acute coronary event ([@b8]). Temporarily discontinuing therapy for a day appears to be safe ([@b64]), but high-risk patients are probably at increased risk after three days ([@b29]). It is likely that continued statin administration will improve outcome further, as in patients who experience acute coronary syndromes, the outcome continues to improve with prolonged statin administration ([@b21]; [@b5]), and vascular patients probably benefit from long-term statin therapy anyway ([@b51]; [@b24]).

Conclusion
==========

There is growing evidence in the world literature to suggest that perioperative statin therapy is cost-effective in reducing morbidity and mortality in elective vascular surgery. In a pharmaco-economic analysis of two prospective studies examining the utility of statins in the perioperative period in patients undergoing major vascular surgery, [@b10] showed the number-needed-to-treat to prevent an adverse cardiac event was fifteen. Statins may be under-prescribed in vascular surgery patients, especially since many of them have clinically occult cardiac ischemia.

Despite a number of interesting potential benefits and a good safety profile, there is still a lack of large multicenter level I evidence to support the routine use of statins during noncardiac surgery, and most of the evidence is from retrospective cohort studies ([@b12]). Although arguments based on biologic plausibility, cohort series, small randomized trials and extrapolation from nonsurgical cohorts may be misleading, there is already overwhelming evidence of efficacy. A large multi-centre randomized control trial on perioperative statin use may be difficult to conduct as there is overwhelming evidence to suggest that statins have a beneficial cardiovascular protective effect, whether the patient is undergoing surgery or not. Some authors may consider it unethical to with-hold statin treatment to conduct such a trial. Others have shown that in order to reduce the perioperative risk of myocardial events by 25%, at least 6000 patients would need to be recruited for such a study ([@b34]). Up to now, there is no consensus to support a role for the routine administration in patients without established coronary artery disease undergoing noncardiac surgery; although some have suggested that perioperative statin therapy for patients undergoing vascular surgery may present the most cost-effective use of statin therapy yet described ([@b10]). Rather to examine the perioperative use of statin, future trials may be aimed at determining the optimal duration and dosage of perioperative statin therapy ([@b54]).
